Mass Spectrometry Market worth $10.78 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 8, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Mass Spectrometry Market is projected to grow from about USD 7.07 billion in 2026 to USD 10.78 billion by 2031, at a CAGR of 6.4%.

Browse 250 market data Tables and 50 Figures spread through 300 Pages and in-depth TOC on 'Electrosurgery Market - Global Forecast to 2031'

Mass Spectrometry Market Size & Forecast:

• Market Size Available for Years: 2025–2031
• 2026 Market Size: USD 7.07 billion
• 2031 Projected Market Size: USD 10.78 billion
• CAGR (2026–2031): 8.8%

Mass Spectrometry Market Trends & Insights:

• By product, the software & services segment is expected to register the highest CAGR of 9.6% during the forecast period.
• By inlet type, the LC-MS segment held the largest share of 57.5% in the overall mass spectrometry market in 2025.
• By end user, the pharmaceutical companies held a 24% share of the mass spectrometry market in 2025.
• By application, the omics research segment is expected to register the highest CAGR of 8.7%.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=437

The global mass spectrometry market is experiencing significant growth due to rising pharmaceutical investments, expanding clinical research activities, and the increasing need for high-precision quality control across the food, beverage, and life sciences industries. Pharmaceutical and biopharmaceutical manufacturers are increasingly adopting advanced mass spectrometry techniques to enhance product quality assurance, impurity profiling, and regulatory compliance during drug manufacturing and development processes. In the food & beverage sector, growing concerns regarding food safety, contamination detection, and trace-level analysis are further accelerating the adoption of mass spectrometry systems for scalable and highly accurate quality control applications.

Another major trend shaping the market is the rapid expansion of clinical development outsourcing and bioanalytical testing services. Contract research organizations (CROs) and bioanalytical laboratories across North America and other major pharmaceutical hubs are making substantial investments in advanced LC-MS/MS and high-resolution mass spectrometry platforms to support outsourced drug development programs. As pharmaceutical companies continue shifting toward outsourced clinical research, demand for recurring bioanalytical testing, pharmacokinetic analysis, biomarker validation, and therapeutic drug monitoring is increasing significantly. Additionally, recent trends such as automation-enabled mass spectrometry workflows, AI-assisted data analysis, multi-omics research integration, and growing adoption of high-throughput analytical platforms are further contributing to the expansion of the mass spectrometry market.

The instruments segment dominated the overall market in 2025.

Based on product, the mass spectrometry market is segmented into instruments, software, and services. The instruments segment accounts for the largest share of the mass spectrometry market. Hospitals and large diagnostic networks are increasingly deploying automated benchtop hybrid MS systems for decentralized high-volume clinical testing, including endocrinology, therapeutic drug monitoring, toxicology, steroid profiling, and newborn screening. Unlike earlier adoption cycles focused mainly on research laboratories, current purchasing decisions are being driven by long-term assay menu expansion strategies and laboratory consolidation initiatives. Vendors are therefore launching compact, walkaway automation-enabled hybrid MS systems with pre-validated clinical workflows, integrated middleware, AI-assisted spectral interpretation, and simplified operation layers designed specifically for routine clinical laboratory environments. This is significantly expanding adoption among mid-sized hospitals and regional diagnostic laboratories that previously depended on immunoassays or outsourced testing services.

Another high-impact trend reshaping the market is the emergence of lifecycle-driven replacement economics and "clinical insourcing" strategies across healthcare systems. Large hospitals, reference laboratories, and integrated delivery networks are increasingly internalizing high-value mass spectrometry testing to reduce turnaround time, improve reimbursement capture, and strengthen data ownership for precision medicine programs. This shift is accelerating demand for next-generation hybrid MS platforms with higher multiplexing capability, ultra-fast polarity switching, and cloud-connected remote diagnostics that support continuous assay upgrades without replacing the full instrument stack.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=437

The LC-MS segment dominated the overall mass spectrometry market in 2025.

By inlet type, the mass spectrometry market is categorized into LC-MS, GC-MS, ICP-MS, and other techniques. The advent of new applications of LC-MS for testing emerging contaminants from third-party testing service providers and labs has increased in the last three years. All these conditions have helped LC-MS to acquire a major share in the mass spectrometry market. The use of LC-MS has expanded over the years as it offers both selectivity and specificity in analysis. With advances in mass spectrometry, the sensitivity and accuracy of this technique have further increased, allowing for the detection and identification of low-level analytes in complex sample matrices. Liquid chromatography (LC) is a technique widely used to separate compounds from a sample before analysis and is frequently coupled to mass spectrometry.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=437

Top Companies in Mass Spectrometry Market:

The Top Companies in Mass Spectrometry Market include Agilent Technologies, Inc. (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Waters Corporation (US), Bruker Corporation (US), Shimadzu Corporation (Japan), PerkinElmer, Inc (US) Jeol, Ltd (Japan), Jasco (Japan), Teledyne Technologies Incorporated (US), and MKS Instruments (US), and others.

Browse Adjacent Markets: Analytical and Scientific Instrumentation Market Research Reports & Consulting

Related Reports:

Esoteric Testing Market - Global Forecast to 2029

Pharma Mass Spectrometry Market - Global Forecast to 2031

Biomarkers Market - Global Forecast to 2030

PFAS Testing Market - Global Forecast to 2030

Drug Discovery Services Market - Global Forecast to 2030

About MarketsandMarkets™ 

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/